A New Era of Innovations in Oncology

The fight against cancer is an urgent one. There are millions of people around the world suffering from cancer today. That’s why Pfizer is investing significant capital in the next generation of potential breakthroughs in cancer treatment.

The company continues to advance its oncology portfolio, with several innovations on the horizon in 2023 including the potential launch of two cancer medicines with blockbuster potential. Pfizer’s oncology portfolio overall includes an industry-leading portfolio of 24 innovative oncology medicines and biosimilars, including seven therapies to treat hematologic malignancies.

The company has been at the forefront of the oncology market for more than a decade, pioneering innovative and life-saving new treatments for multiple cancers and tumor types.

Learn more about Pfizer’s oncology portfolio.

Potential Therapy for Hematologic Malignancies

Hematologic malignancies are cancers that begin in blood-forming tissue, affecting the blood, bone marrow, or lymph nodes. The three most common types of hematologic malignancies are leukemia, lymphoma, and multiple myeloma. Though the prevalence of these cancers is relatively low, there are significant unmet needs in their treatment.

Pfizer is working on a treatment for people with multiple myeloma, that works by activating T-cells to kill the myeloma cells. If successful, it has the potential to reach a greater number of patients than some other immunotherapies given the convenient route of administration, providing an alternative option for physicians and their patients. While there are numerous approved treatments for multiple myeloma, relapse rates for relapsed or refractory multiple myeloma (RRMM) are high, and patients often find themselves with few therapeutic options, as they develop resistance to successive treatments.^[1]

In December 2022, Pfizer announced follow-up data from the pivotal Phase 2 MagnetisMM3-clinical trial in patients with RRMM. Based on that data, the U.S. Food and Drug Administration granted priority review and the European Medicines Agency also accepted the marketing authorization application for the treatment for review. If approved, the company believes the medicine has the potential to become the next standard of care for multiple myeloma.

Potential Combination Treatment for Prostate Cancer

Despite great advancements in treatment, prostate cancer remains the second most common cancer in men and the fifth most common cause of cancer death among men globally.^[2] Within five-to-seven years of diagnosis, between 10-20% of patients develop metastatic castration-resistant prostate cancer (mCRPC), a cancer that has spread beyond the prostate gland, undeterred by medical or surgical interventions.^[3] Patients with mCRPC experience poor outcomes, shorter duration responses, and high rates of morbidity.

In February 2023, Pfizer shared results from its Phase 3 TALAPRO-2 trial evaluating an investigatory combination treatment in men with mCRPC, with or without homologous recombination repair (HRR) gene mutations. The investigatory treatment combines an oral poly ADP-ribose polymerase (PARP) inhibitor with an androgen receptor inhibitor.

Based on the data from TALAPRO-2, the company has sought regulatory approval and is working with global regulatory authorities to bring this potential treatment to men with mCRPC.

Pfizer hopes to receive regulatory approval and launch both treatments in 2023. Each underscore the company’s longstanding commitment to pursuing breakthroughs that have the potential to improve outcomes for patients living with cancer around the world.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.

[1] American Cancer Society. Multiple Myeloma. Available at cancer.org. Accessed Feb. 8, 2023.

[2] Prostate Cancer Statistics. World Research Fund International. Available at wcrf.org. Accessed 11-09-2022.

[3] Kirby M, et al. Int J Clin Pract. 2011;11:1180-1192.

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.